EUVIMEDEUVIMED entdecken
Crossref

Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia

Huidan Lu, Kaixin Zhang, Wanying Zhang, Wenting Zhang, Jicheng Wu, Xinliang Ming, Yuqiao Huang, Feng Xu, Ben Wang

Trends in Biotechnology · 2025-09 · 43 (9) · 2276-2303

DOI: 10.1016/j.tibtech.2025.05.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Biotechnology, 2025-09. Verfasst von Huidan Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Hauptthemen laut MEDLINE: Teicoplanin, Neutrophils, Anti-Bacterial Agents, Pneumonia, Staphylococcal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Postdoctoral Research Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia has a high clinical incidence and is associated with a significant mortality risk. The existence of intracellular pathogens and the infection-induced swarming of neutrophils exacerbate the challenges in treating pneumonia. Here, we addressed these issues by developing a platform based on neutrophilic membrane-camouflaged teicoplanin (Teic@NEV) to kill bacteria in tissue and prevent inflammatory lung injury associated with MRSA pneumonia. Teic@NEV improved the efficiency of drug entry into cells, meaningfully increasing the intracellular drug concentration in infected cells and eliminating intracellular MRSA. Moreover, Teic@NEV enhanced the penetration of teicoplanin into the biofilm and improved antimicrobial and antibiofilm activities in vitro. Surprisingly, Teic@NEV delivered teicoplanin specifically to sites of inflammation and reduced lung injury by hindering neutrophil swarming in vivo. Thus, this platform represents an effective strategy to limit neutrophil swarming and kill intracellular pathogens in patients with MRSA pneumonia, demonstrating its significant potential for use in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninNeutrophilsAnti-Bacterial AgentsPneumonia, StaphylococcalPneumoniaMethicillin-Resistant Staphylococcus aureusHumansAnimalsBiofilmsMiceCell MembraneInflammation

Stichwörter der Autor:innen

MRSAbiomimetic nanocarriersintracellular bacterianeutrophil swarmingpneumonia

Substanzen

TeicoplaninAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; State Key Laboratory of Transvascular Implantation Devices, Hangzh…
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Institute of…
  • Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address: xufeng99@zju.edu.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Postdoctoral Research Foundation of China
  • China Postdoctoral Science Foundation
  • Fundamental Research Funds for the Central Universities
  • Key Research and Development Program of Zhejiang Province
  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Lu, H., Zhang, K., Zhang, W., Zhang, W., Wu, J., Ming, X., Huang, Y., Xu, F., & Wang, B. (2025). Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia. Trends in Biotechnology, 43(9), 2276-2303. https://doi.org/10.1016/j.tibtech.2025.05.009

Vancouver

Lu H, Zhang K, Zhang W, Zhang W, Wu J, Ming X, et al. Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia. Trends in Biotechnology. 2025;43(9):2276-2303. doi:10.1016/j.tibtech.2025.05.009

BibTeX
@article{Lu2025,
  author = {Lu, Huidan and Zhang, Kaixin and Zhang, Wanying and Zhang, Wenting and Wu, Jicheng and Ming, Xinliang and Huang, Yuqiao and Xu, Feng and Wang, Ben},
  title = {Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia},
  journal = {Trends in Biotechnology},
  year = {2025},
  volume = {43},
  number = {9},
  pages = {2276--2303},
  doi = {10.1016/j.tibtech.2025.05.009}
}
Kostenlos starten →